- Home
- AUTL vs SOPH Comparison
AUTL vs SOPH Comparison
Compare AUTL & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | SOPH |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 367.7M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AUTL | SOPH |
|---|---|---|
| Price | $1.41 | $5.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $8.50 | $7.00 |
| AVG Volume (30 Days) | ★ 1.4M | 96.2K |
| Earning Date | 05-07-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $669.62 | $16.16 |
| Revenue Next Year | $79.78 | $17.56 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.11 | $2.58 |
| 52 Week High | $2.70 | $5.70 |
Technical Indicators
Market Signals| Indicator | AUTL | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 66.89 |
| Support Level | $1.27 | $4.54 |
| Resistance Level | $1.52 | $5.30 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 14.29 | 90.33 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.